Retinal Research Institute – Phoenix
Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.
We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions
Mission / Purpose
Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.
Keep up with new research and findings from recent studies and trials.
Current Studies & Trials
Find out what current studies and trials we are enrolling for.
Interested in a Clinical Trial?
If you or someone you know is interested in more information about our clinical research trials, please contact us.
Dr. Mark Barakat’s Virtual ASRS Interview with Nathan Steinle, MD/ Uncategorized /by retinalconsultants
Watch Dr. Mark R. Barakat be interviewed by Nathan Steinle, MD from California Retina Consultants following his presentation at the virtual 2020 ASRS convention. In his presentation, Dr. Barakat discusses the Kodiac trials currently undergoing at the Retinal Research Institute.
Pravin U. Dugel MD: Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial/ Uncategorized /by retinalconsultants
CINCINNATI–(BUSINESS WIRE)– Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients […]